ProCE Banner Activity

Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations

Slideset Download
Conference Coverage
Results from a phase I trial showed that patritumab deruxtecan was active in heavily pretreated patients with unresectable locally advanced or metastatic NSCLC without EGFR activating mutations.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab